Nuvectis Pharma Q1 Cash Falls to $25.1M, Net Loss Widens to $6.1M
Nuvectis Pharma closed Q1 with $25.1 M in cash, down from $31.6 M at year-end, and posted a $6.1 M net loss, up $0.8 M year-over-year, driven by increased R&D and G&A spending. Its NXP900 Phase 1b trial is enrolling monotherapy and sotorasib combination arms and expects preliminary data this summer after preclinical synergy results.
1. Q1 Financial Results
Nuvectis Pharma reported cash and cash equivalents of $25.1 million as of March 31, 2026, down from $31.6 million at December 31, 2025. The company recorded a $6.1 million net loss for the quarter versus $5.3 million in Q1 2025, reflecting $4.1 million in R&D expenses and $2.2 million in G&A costs.
2. NXP900 Phase 1b Trial Update
The NXP900 Phase 1b program continues to enroll patients at select U.S. sites across monotherapy and combination arms with sotorasib. Management anticipates a preliminary data readout in summer 2026 to guide further clinical development.
3. Preclinical Combination Data and Strategic Outlook
At the 2026 AACR conference, preclinical data demonstrated clear synergy between NXP900 and sotorasib in both sensitive and resistant NSCLC models. The company remains focused on key clinical milestones and financial discipline through 2026 and beyond.